All In Biotech

Drug Trial Radar · NCT06249438

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

An Exploratory Clinical Study of Cluster of Differentiation Antigen 20(CD20)/Anti-B-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Mar 20, 2024

Primary completion

Mar 2027

Study completion Mar 2040

Sponsor

Lead sponsor
RenJi HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AbelZeta Inc.
First posted
Feb 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy

Conditions

  • Systemic Lupus Erythematosus (SLE)
  • Immune-mediated Necrotizing Myopathy (IMNM)
  • Neuromyelitis Optica Spectrum Disorders (NMOSD)
  • Multiple Sclerosis (MS)
  • Myasthenia Gravis
  • Systemic Sclerosis (SSc)

Interventions

  • CD20/BCMA-directed CAR-T cellsBiological

    Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events [Safety and Tolerability]Time frame: Throughout the first 24 months follow up period completion (3 years),DLTs will be observed/collected throughout the 28 days post C-CAR168 infusion
  2. The subsequent recommended dose of C-CAR168 in patients with autoimmune diseases refractory to standard therapyTime frame: Throughout the first 24 months follow up period completion (3 years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.